A chemical model suggesting the maximum radiolabeled somatostatin analogue tumor uptake, in the presence of unlabeled somatostatin.

Somatostatin analogues (SSA), both radiolabeled and unlabeled play an important role in the management of carcinoid tumors. They are often administered in parallel, the unlabeled analogue for treating the carcinoid tumors' symptoms and the radiolabeled one for imaging tumors foci. There is a debate about when is the optimum time for a somatostatin receptor scintigraphy during treatment.

Brown tumors; a possible pitfall in diagnosing metastatic disease.

Brown tumors (BT) are scarcely diagnosed and present a possible diagnostic pitfall in imaging modalities. Imaging modalities and especially positron emission tomography cannot differentiate between brown tumors and metastatic foci and only clinical diagnosis of hyperparathyroidism and histology will support the diagnosis. We describe the histology, clinical expression, significance and the differential diagnosis of BT.